- Home
- MPW vs BEAM Comparison
MPW vs BEAM Comparison
Compare MPW & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- BEAM
- Stock Information
- Founded
- MPW 2003
- BEAM 2017
- Country
- MPW United States
- BEAM United States
- Employees
- MPW N/A
- BEAM N/A
- Industry
- MPW Real Estate Investment Trusts
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPW Real Estate
- BEAM Health Care
- Exchange
- MPW Nasdaq
- BEAM Nasdaq
- Market Cap
- MPW 2.4B
- BEAM 1.9B
- IPO Year
- MPW 2005
- BEAM 2020
- Fundamental
- Price
- MPW $4.33
- BEAM $24.41
- Analyst Decision
- MPW Hold
- BEAM Buy
- Analyst Count
- MPW 6
- BEAM 10
- Target Price
- MPW $4.92
- BEAM $47.67
- AVG Volume (30 Days)
- MPW 13.8M
- BEAM 1.2M
- Earning Date
- MPW 02-19-2025
- BEAM 02-25-2025
- Dividend Yield
- MPW 7.44%
- BEAM N/A
- EPS Growth
- MPW N/A
- BEAM N/A
- EPS
- MPW N/A
- BEAM N/A
- Revenue
- MPW $660,172,000.00
- BEAM $349,643,000.00
- Revenue This Year
- MPW N/A
- BEAM N/A
- Revenue Next Year
- MPW N/A
- BEAM $14.08
- P/E Ratio
- MPW N/A
- BEAM N/A
- Revenue Growth
- MPW N/A
- BEAM 328.73
- 52 Week Low
- MPW $3.08
- BEAM $20.84
- 52 Week High
- MPW $6.55
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- MPW 61.22
- BEAM 42.12
- Support Level
- MPW $3.93
- BEAM $22.50
- Resistance Level
- MPW $4.23
- BEAM $28.39
- Average True Range (ATR)
- MPW 0.23
- BEAM 1.56
- MACD
- MPW 0.06
- BEAM -0.33
- Stochastic Oscillator
- MPW 91.11
- BEAM 27.67
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc is a healthcare facility REIT. The company operates one segment, which owns and leases healthcare facilities. The vast majority of Medical's revenue is generated in the United States, followed by Germany and the United Kingdom. It provides financing for a variety of facilities that require funds for acquisitions, sale-leasebacks, new developments, and expansion projects.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.